Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-MMP7 in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
NCT05537025Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 6
01
Overview
Phase 2, randomised trial in idiopathic pulmonary fibrosis (IPF) comparing ARO-MMP7 with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Jan 2023; status: completed.
02
Drugs
SRP-1002
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05537025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537025.